Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
ID: 347576Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347576

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-168.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)" aimed at stimulating research in the discovery and development of novel small molecules for psychiatric disorders. The objective is to support the development and validation of screening assays that can lead to innovative biological models and screening techniques relevant to mental health conditions such as depression and schizophrenia. This initiative is crucial for enhancing drug discovery processes and ultimately alleviating suffering from mental health disorders. Interested applicants, including various educational and nonprofit institutions, can submit proposals until May 7, 2026, with no cap on budgets, provided they reflect actual project needs. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-168.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-168-Full-Announcement.html
    PAR-23-168.html
    The National Institute of Mental Health (NIMH) within the Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) to support the development and validation of screening assays for discovering validated chemical hits aimed at treating mental illnesses. The funding opportunity (NOFO number PAR-23-168) emphasizes three key research stages: assay development, primary screen implementation, and hit validation. Applications are encouraged from various eligible organizations, including higher education institutions, nonprofits, and for-profit organizations, allowing diverse applicants to participate in advancing mental health research. Funding is available for projects that propose innovative biological models and screening techniques relevant to psychiatric disorders like depression and schizophrenia. The application deadlines span from June 2023 to May 2026, but only projects not proposing clinical trials are eligible. Although there is no cap on application budgets, they must reflect actual project needs. The review process will evaluate factors including significance, innovation, and the appropriateness of the research approach. The overarching goal is to enhance drug discovery processes for psychiatric treatments, ultimately contributing to NIMH's mission of alleviating suffering from mental health disorders.
    Similar Opportunities
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral assays in animal models to enhance the therapeutic development pipeline for mental illnesses, focusing on optimizing measures that reflect clinically relevant brain processes. The program encourages research proposals that assess the sensitivity and specificity of these assays as screening tools and promote collaboration between preclinical and clinical studies to facilitate translation to human applications. Interested applicants can apply for grants up to $250,000, with the application deadline set for September 7, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Studies of Mental Illness (Collaborative R01)" aimed at supporting multidisciplinary clinical studies focused on mental health, particularly in areas such as genetics, biomarkers, and various mental illnesses. This initiative encourages collaboration across multiple sites to enhance sample sizes and diversity in participant recruitment, specifically targeting health disparity populations. The program allows for a project period of up to five years with no explicit budget limits, although proposed budgets must be well justified. Interested applicants, including various educational and nonprofit institutions, should submit their applications by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) for the development and screening of assays aimed at discovering small molecules that can serve as chemical probes, drugs, or immunomodulators. This initiative seeks to support research that elucidates disease biology and therapeutic targets, particularly focusing on cancer-related applications, including the development of assays, high-throughput screening, hit validation, and optimization of lead compounds. The opportunity is open to a wide range of eligible applicants, including educational institutions, nonprofits, and tribal organizations, with no cost-sharing requirement and a project period of up to three years. Interested parties should submit their applications electronically through Grants.gov by the deadline of September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG)" aimed at advancing the treatment of mental disorders and alcohol use disorder through innovative drug and device therapies. This cooperative agreement encourages applications from partnerships between academia and industry, focusing on the discovery, preclinical development, and proof of concept testing of new therapeutic interventions, including pharmacologic and neuromodulatory tools. The initiative is crucial for fostering collaboration to expedite the development of effective treatments for pressing mental health issues, with applications due by February 24, 2025. Interested applicants can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.